Indaptus Therapeutics (INDP) Competitors $7.30 -0.86 (-10.54%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$7.40 +0.09 (+1.30%) As of 08/1/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. DARE, AYTU, RVPH, CVKD, ELEV, VYNE, RLMD, CYCC, MBRX, and PASGShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Dare Bioscience (DARE), Aytu BioPharma (AYTU), Reviva Pharmaceuticals (RVPH), Cadrenal Therapeutics (CVKD), Elevation Oncology (ELEV), VYNE Therapeutics (VYNE), Relmada Therapeutics (RLMD), Cyclacel Pharmaceuticals (CYCC), Moleculin Biotech (MBRX), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Dare Bioscience Aytu BioPharma Reviva Pharmaceuticals Cadrenal Therapeutics Elevation Oncology VYNE Therapeutics Relmada Therapeutics Cyclacel Pharmaceuticals Moleculin Biotech Passage Bio Indaptus Therapeutics (NASDAQ:INDP) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk. Do analysts recommend INDP or DARE? Indaptus Therapeutics presently has a consensus target price of $238.00, suggesting a potential upside of 3,160.27%. Dare Bioscience has a consensus target price of $12.00, suggesting a potential upside of 395.87%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Indaptus Therapeutics is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, INDP or DARE? Indaptus Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Do insiders and institutionals believe in INDP or DARE? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 20.8% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 4.0% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings and valuation, INDP or DARE? Dare Bioscience has higher revenue and earnings than Indaptus Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$41.74-0.17Dare Bioscience$10K2,185.26-$4.05M-$0.17-14.24 Is INDP or DARE more profitable? Dare Bioscience's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -333.02% -216.36% Dare Bioscience N/A N/A -8.14% Does the media prefer INDP or DARE? In the previous week, Dare Bioscience had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Dare Bioscience and 0 mentions for Indaptus Therapeutics. Dare Bioscience's average media sentiment score of 1.06 beat Indaptus Therapeutics' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Indaptus Therapeutics Neutral Dare Bioscience Positive SummaryIndaptus Therapeutics and Dare Bioscience tied by winning 7 of the 14 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.67M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-0.178.9728.6723.80Price / SalesN/A639.67422.3188.12Price / CashN/A157.7635.4557.96Price / Book0.674.838.275.55Net Income-$15.02M$31.62M$3.24B$259.03M7 Day Performance-26.41%-5.28%-3.63%-4.56%1 Month Performance-34.76%4.38%4.40%4.49%1 Year Performance-86.21%-2.49%25.97%18.05% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.8798 of 5 stars$7.30-10.5%$238.00+3,160.3%-87.3%$4.67MN/A-0.176DAREDare Bioscience1.7743 of 5 stars$2.48-2.7%$12.00+383.9%-29.0%$22.39M$10K-14.5930Positive NewsShort Interest ↑AYTUAytu BioPharma3.1557 of 5 stars$2.49-5.5%$10.00+302.4%-8.0%$22.32M$81M-3.45160RVPHReviva Pharmaceuticals2.5995 of 5 stars$0.46-6.5%$9.00+1,865.1%-59.3%$21.99MN/A-0.585Short Interest ↑High Trading VolumeCVKDCadrenal Therapeutics2.1367 of 5 stars$11.04-4.7%$32.00+190.0%N/A$21.67MN/A-1.194Positive NewsUpcoming EarningsELEVElevation Oncology2.7444 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540Upcoming EarningsVYNEVYNE Therapeutics2.5133 of 5 stars$1.41-2.8%$6.25+343.3%-80.6%$21.37M$605K-1.4230Trending NewsAnalyst DowngradeRLMDRelmada Therapeutics4.4482 of 5 stars$0.63-1.8%$5.00+694.9%-84.0%$20.75MN/A-0.2510News CoverageUpcoming EarningsCYCCCyclacel Pharmaceuticals0.1781 of 5 stars$13.15-14.5%N/A-97.6%$20.72M$40K-0.0214Short Interest ↑Gap DownMBRXMoleculin Biotech2.8807 of 5 stars$0.69+24.5%$4.00+483.9%-70.7%$20.69MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap DownPASGPassage Bio3.8064 of 5 stars$6.61-6.2%$150.00+2,169.3%-69.8%$20.62MN/A-0.32130Gap Down Related Companies and Tools Related Companies DARE Alternatives AYTU Alternatives RVPH Alternatives CVKD Alternatives ELEV Alternatives VYNE Alternatives RLMD Alternatives CYCC Alternatives MBRX Alternatives PASG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts